Mikrobiyoloji Bulteni | VOL. 56
Read

Investigation of pncA, rpsA and panD Gene Mutations Associated with Resistance in Pyrazinamide-Resistant Mycobacterium tuberculosis Isolates and Spoligotyping

Publication Date Apr 25, 2022

Abstract

Pyrazinamide (PZA) is one of the first-line anti-tuberculous drugs used in the treatment of tuberculosis (TB). Considering the ability of PZA to shorten the treatment period from 9-12 months to six months by eliminating persistent bacilli, it appears to be an important cornerstone of TB therapy. While the main mechanism causing the PZA resistance is pncA mutations at a rate of 70-97%, it has been determined that rpsA and panD mutations can also cause resistance. In this study, we aimed to investigate the pncA, rpsA and panD gene mutations, the efficiency of the pyrazinamidase (PZAse) enzyme test in determining PZA resistance, the drug susceptibility and their families in PZA-resistant Mycobacterium tuberculosis isolates. Totally 46 PZA resistant M.tuberculosis isolates were included in the study. The pncA, rpsA and panD mutations caused by PZA resistance were investigated by in-house PCR followed by DNA sequencing method. Drug susceptibility was determined with Bactec MGIT 960 (Becton Dickinson, USA) system, the presence of PZAse was evaluated by colorimetric PZAse enzyme assay and the families were determined by the spoligotyping method. Of the 46 PZA-resistant isolates, 24 (52.2%) were identified as PZA monoresistant, 11 (23.9%) multidrug resistant (MDR)-TB and 11 (23.9%) poly drug resistant (PDR)-TB. Gene mutations associated with resistance were detected in 73.9% (34) of PZA-resistant M.tuberculosis isolates. The pncA, rpsA and panD mutations were found in 71.7% (33), 28.2% (12) and 4.3% (2) of the isolates, respectively...

Concepts

pncA Gene Mutations pncA Mutations rpsA Gene pncA Gene Pyrazinamide Resistance PZA-resistant Isolates Gene Mutations rpsA Mutations Pyrazinamide panD Mutations

Round-ups are the summaries of handpicked papers around trending topics published every week. These would enable you to scan through a collection of papers and decide if the paper is relevant to you before actually investing time into reading it.

Coronavirus Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  5

Introduction: Test solutions (Biotrue, renu Advanced [Bausch and Lomb], ACUVUE RevitaLens [Johnson and Johnson Vision], cleadew [Ophtecs corp.] or AOS...

Read More

Good health Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  2

Patient and public involvement in health care is considered indispensable in the way we conduct daily pediatric neurology practice, and in the develop...

Read More

Quality Of Education Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  5

Ingenta is not the publisher of the publication content on this website. The responsibility for the publication content rests with the publishers prov...

Read More

Gender Equality Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  3

Introduction: As of early March 2022, the COVID-19 pandemic has killed more 5.9 million people worldwide, and infected more than 437 million.

Read More

Coronavirus Pandemic

You can also read COVID related content on R COVID-19

R ProductsCOVID-19

ONE PROBLEM . ONE PURPOSE . ONE PLACE

Creating the world’s largest AI-driven & human-curated collection of research, news, expert recommendations and educational resources on COVID-19

COVID-19 Dashboard

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on “as is” basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The Copyright Law.